Partnering — Adiso Therapeutics

Partnering Opportunities

We welcome the opportunity to collaborate with likeminded strategic partners who share our dedication to making a significant impact on the lives of patients and their families. This commitment coupled with our passion for scientific research and innovation, have propelled us towards groundbreaking technologies and potential first in class therapies. Through a collaborative partnership, you can contribute your expertise and valuable insights to help guide the development of products and solutions that align with your organizational objectives. Our current partnering portfolio of therapeutics, each with novel mechanisms of action, presents a unique opportunity to influence the trajectory of our ongoing research and development in inflammatory diseases with high unmet need.

Partnering Pipeline

Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)

Multimodal activity contributes to efficacy

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 CDI

Prevention of CDI Recurrence

ADS024 is an orally dosed, naturally occurring single strain live biotherapeutic product (SS-LBP) with a multimodal mechanism of action. ADS024 is bactericidal against Clostridioides difficile, degrades Toxins A and B, protects epithelial cells by inhibiting toxin mediated caspase 3 activation and maintains gut homeostasis. ADS024 is manufactured from a pure clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from human donor fecal material.

ADS024 UC

Ulcerative Colitis

ADS024 is an orally dosed, naturally occurring single strain live biotherapeutic product (SS-LBP) with a multimodal mechanism of action. ADS024 modulates inflammation and simultaneously protects the gut barrier function and integrity. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from human donor fecal material.

ADS024 Gut-Brain Axis

Central Neuroinflammation

ADS024 has demonstrated pre-clinical efficacy in animal models of central neuroinflammatory disease including Multiple Sclerosis, Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis, Autism and others. Adiso is pursuing studies on the selective GPCR agonism-mediated mechanism of action of ADS024 on the Gut-Brain Axis.

ADS012 Gut-Brain Axis

Peripheral Neuroinflammation

ADS012 has demonstrated pre-clinical efficacy in models of peripheral neuroinflammatory disease including Chemotherapy Induced Peripheral Neuropathy and Morphine Antinociceptive Tolerance. Adiso is pursuing studies on the impact of ADS012 on the Gut-Brain Axis.